Stock Scorecard
Stock Summary for BioNTech SE (BNTX) - $102.70 as of 11/26/2025 8:09:19 PM EST
Total Score
10 out of 30
Safety Score
49 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BNTX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BNTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BNTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BNTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for BNTX (49 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 9 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for BNTX
Financial Details for BNTX
Company Overview |
|
|---|---|
| Ticker | BNTX |
| Company Name | BioNTech SE |
| Country | USA |
| Description | BioNTech SE, headquartered in Mainz, Germany, is a pioneering biotechnology company at the forefront of developing and commercializing innovative immunotherapies aimed at addressing cancer and infectious diseases. Renowned for its rapid collaboration with Pfizer in bringing a transformative COVID-19 vaccine to market, BioNTech has established a robust pipeline focused on personalized cancer therapies and cutting-edge mRNA-based treatments. The company’s emphasis on precision medicine, combined with its strong commitment to scientific research and strategic alliances, positions BioNTech as a leader in the evolving biotechnology sector, poised to address significant unmet medical needs globally. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 102.70 |
| Price 4 Years Ago | 252.01 |
| Last Day Price Updated | 11/26/2025 8:09:19 PM EST |
| Last Day Volume | 1,046,067 |
| Average Daily Volume | 784,680 |
| 52-Week High | 129.27 |
| 52-Week Low | 81.20 |
| Last Price to 52 Week Low | 26.48% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.18 |
| Sector PE | 88.38 |
| 5-Year Average PE | -6.09 |
| Free Cash Flow Ratio | 2.45 |
| Industry Free Cash Flow Ratio | 13.63 |
| Sector Free Cash Flow Ratio | 28.18 |
| Current Ratio Most Recent Quarter | 7.12 |
| Total Cash Per Share | 41.97 |
| Book Value Per Share Most Recent Quarter | 76.84 |
| Price to Book Ratio | 1.09 |
| Industry Price to Book Ratio | 33.42 |
| Sector Price to Book Ratio | 32.98 |
| Price to Sales Ratio Twelve Trailing Months | 7.61 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.78 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.65 |
| Analyst Buy Ratings | 13 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 240,455,000 |
| Market Capitalization | 24,694,728,500 |
| Institutional Ownership | 22.50% |
Dividends |
|
| Ex-Dividend Date | 6/2/2022 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 2.1322 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 1 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -43.20% |
| Annual Earnings Growth | -171.51% |
| Reported EPS 12 Trailing Months | -2.75 |
| Reported EPS Past Year | -3.54 |
| Reported EPS Prior Year | -2.81 |
| Net Income Twelve Trailing Months | -571,600,000 |
| Net Income Past Year | -665,300,000 |
| Net Income Prior Year | 930,300,000 |
| Quarterly Revenue Growth YOY | 22.00% |
| 5-Year Revenue Growth | 90.87% |
| Operating Margin Twelve Trailing Months | -2.17% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 10,092,900,000 |
| Total Cash Past Year | 9,761,900,000 |
| Total Cash Prior Year | 11,663,700,000 |
| Net Cash Position Most Recent Quarter | 9,900,900,000 |
| Net Cash Position Past Year | 9,547,200,000 |
| Long Term Debt Past Year | 214,700,000 |
| Long Term Debt Prior Year | 191,000,000 |
| Total Debt Most Recent Quarter | 192,000,000 |
| Equity to Debt Ratio Past Year | 0.99 |
| Equity to Debt Ratio Most Recent Quarter | 0.99 |
| Total Stockholder Equity Past Year | 19,411,100,000 |
| Total Stockholder Equity Prior Year | 20,245,900,000 |
| Total Stockholder Equity Most Recent Quarter | 18,477,300,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -1,698,505,371 |
| Free Cash Flow Per Share Twelve Trailing Months | -7.06 |
| Free Cash Flow Past Year | -244,600,000 |
| Free Cash Flow Prior Year | 4,665,900,000 |
Options |
|
| Put/Call Ratio | 0.24 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -1.18 |
| MACD Signal | -0.25 |
| 20-Day Bollinger Lower Band | 92.50 |
| 20-Day Bollinger Middle Band | 104.64 |
| 20-Day Bollinger Upper Band | 116.79 |
| Beta | 1.31 |
| RSI | 32.99 |
| 50-Day SMA | 106.57 |
| 150-Day SMA | 105.96 |
| 200-Day SMA | 117.67 |
System |
|
| Modified | 11/26/2025 6:18:44 PM EST |